CD19 and hematologic disorder: The use of CARs to specifically redirect NK cells towards tumor targets has already demonstrated high clinical efficacy against CD19-positive hematological malignancies without the severe toxicities and graft-vs-host disease seen with CAR-T cell therapies (5).